Silymarin for ulcerative colitis
Treatments studied
Part of Digestive system clinical trials.
This study tests whether silymarin (an extract from milk thistle) can help treat ulcerative colitis when added to your usual treatment. It may reduce inflammation and oxidative stress in the colon.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You cannot have serious kidney or liver problems.
- You cannot be pregnant, breastfeeding, or a smoker.
- You cannot be taking corticosteroids (e.g., prednisone) or biologic medicines for your colitis.
- You cannot be taking any other antioxidant supplements like vitamin E or CoQ10.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding alpha lipoic acid (an antioxidant) to your usual mesalamine treatment helps control mild to moderate ulcerative colitis. It is for people newly diagnosed and not on other UC treatments.
This trial studies whether an oral treatment called MS-20 can improve ulcerative colitis (UC) in adults with moderate to severe disease. You may be asked to provide stool samples from home and avoid certain foods and medicines before screening and during the study.
This trial tests a new drug called SAR442970 for adults with moderate to severe ulcerative colitis (UC) that has not responded well to standard treatments or other advanced therapies. The goal is to see if it can reduce symptoms and improve quality of life.
This trial tests an experimental drug (ISM5411) for people with active ulcerative colitis. The goal is to see if the drug can reduce inflammation and improve symptoms.
This trial tests a new treatment for people with ulcerative colitis (UC) whose disease is active despite taking only mesalamine or sulfasalazine. It aims to find a therapy that can reduce inflammation and improve symptoms.
This study tests adding a medicine called mebendazole (normally used for parasites) to standard mesalamine treatment for people with mild or moderate ulcerative colitis. The goal is to see if it helps control inflammation better than mesalamine alone.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.